Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026)
Gilead Sciences' (GILD) quarterly Other Non-Current Assets came in at $4.6 billion in Q1 2026, up 17.64% YoY from $3.9 billion in Q1 2025, and down 6.01% on a QoQ basis from $4.8 billion in Q4 2025.
Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Other Non-Current Assets data on file, last reported at $4.6 billion in Q1 2026.
- Quarterly Other Non-Current Assets rose 17.64% year-over-year to $4.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 billion (up 17.64% YoY) and the FY2025 annual result came in at $4.8 billion, up 28.55% from the prior year.
- Other Non-Current Assets slipped to $4.6 billion in Q1 2026, from $4.8 billion in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $5.5 billion in Q3 2024 to a low of $3.8 billion in Q4 2024.
- A 5-year average of $4.7 billion and a median of $4.8 billion in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets surged 30.81% — and 2025, when it fell 25.39%.
- Tracing GILD's Other Non-Current Assets over 5 years: stood at $4.8 billion in 2022, then dropped by 0.17% to $4.8 billion in 2023, then dropped by 21.35% to $3.8 billion in 2024, then climbed by 28.55% to $4.8 billion in 2025, then declined by 6.01% to $4.6 billion in 2026.
- The last three Other Non-Current Assets figures came in at $4.6 billion (Q1 2026), $4.8 billion (Q4 2025), and $4.9 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 5.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.75 Bn |
| Mar 31, 2026 | 4.55 Bn |
| Dec 31, 2025 | 4.85 Bn |
| Sep 30, 2025 | 4.87 Bn |
| Jun 30, 2025 | 4.03 Bn |
| Mar 31, 2025 | 3.87 Bn |
| Dec 31, 2024 | 3.77 Bn |
| Sep 30, 2024 | 5.49 Bn |
| Jun 30, 2024 | 4.77 Bn |
| Mar 31, 2024 | 5.19 Bn |
| Dec 31, 2023 | 4.79 Bn |
| Sep 30, 2023 | 4.20 Bn |
| Jun 30, 2023 | 5.11 Bn |
| Mar 31, 2023 | 4.95 Bn |
| Dec 31, 2022 | 4.80 Bn |
| Sep 30, 2022 | 4.62 Bn |
| Jun 30, 2022 | 4.86 Bn |
| Mar 31, 2022 | 5.13 Bn |
| Dec 31, 2021 | 4.96 Bn |
| Sep 30, 2021 | 4.74 Bn |